A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Status:
Active, not recruiting
Trial end date:
2022-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents
with immunomodulatory activity to identify the doses and schedule for combination therapy and
to preliminarily assess the safety, tolerability, pharmacological and clinical activity of
these combinations.